ERLOLIEVA contains Erlotinib, an oral targeted anticancer medicine. It is a tyrosine kinase inhibitor (TKI) that selectively blocks the epidermal growth factor receptor (EGFR), thereby inhibiting tumor cell proliferation and survival—especially in EGFR-mutated cancers.

Erlotinib is used for the treatment of:

1. Non-small cell lung cancer (NSCLC) – EGFR-mutation positive (first-line or subsequent therapy)

2. Locally advanced or metastatic NSCLC – after failure of at least one prior chemotherapy regimen

3. Pancreatic cancer – in combination with gemcitabine

Common side effects:

•  Skin rash (acne-like)

•  Diarrhea

•  Loss of appetite

•  Fatigue

•  Nausea

Serious side effects:

•  Interstitial lung disease (rare but serious)

•  Severe skin reactions

•  Liver enzyme elevation

• Gastrointestinal perforation (rare)

•   Standard dose: 150 mg orally once daily

•  Take on an empty stomach
    (At least 1 hour before or 2 hours after food)

•  Dose adjustment may be required based on tolerance or liver function.

NOTE: This medicine should be taken only under a doctor’s supervision.